Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2020
Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?
10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets. ...
Posted by Michael Wonder on 12 Jul 2020
Why it’s time to abandon the ICER
10 July 2020 - The incremental cost-effectiveness ratio (ICER) is the most commonly reported summary measure for economic evaluations of health ...
Posted by Michael Wonder on 05 Jul 2020
Beyond the numbers: a critique of quantitative multi-criteria decision analysis
1 July 2020 - When setting priorities for health, there is broad agreement that a range of social values and ethical ...
Posted by Michael Wonder on 22 Jun 2020
It’s time to put fairness into focus
19 June 2020 - Medicines New Zealand is today launching a digitally-enabled public awareness platform Fairness in Focus. ...
Posted by Michael Wonder on 17 Jun 2020
CMS’s proposed rule on value-based purchasing for prescription drugs: new tools for negotiating prices for the next generation of therapies
17 June 2020 - The Trump Administration has delivered significant policy advancements to lower the price of drugs and spur greater ...
Posted by Michael Wonder on 16 Jun 2020
Advancing structured decision‐making in drug regulation at the FDA and EMA
11 June 2020 - FDA’s recent benefit‐risk framework was developed for improving the clarity and consistency in communicating the reasoning behind ...
Posted by Michael Wonder on 05 Jun 2020
Independent review of lamotrigine sole supply decision by PHARMAC
5 June 2020 - The review was published on the PHARMAC website today and shared with people who had been ...
Posted by Michael Wonder on 03 Jun 2020
Paying for value from costly medical technologies: a framework for applying value-based payment reforms
2 June 2020 - Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising ...
Posted by Michael Wonder on 02 Jun 2020
Traditional cost effectiveness formulas and precision medicines
1 June 2020 - Cost effectiveness analyses, which are often conducted to evaluate new medicines, use a standardised framework to ...
Posted by Michael Wonder on 21 May 2020
Medicines with one seller and many buyers: strategies to increase the power of the payer
20 May 2020 - Andrew Rintoul and colleagues argue that collaboration and transparency increase the market power of buyers who ...
Posted by Michael Wonder on 15 May 2020
Putting a dollar value on life? Governments already do
11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...
Posted by Michael Wonder on 15 May 2020
International coordination needed to encourage conduct of large, decision-relevant COVID-19 clinical trials
15 May 2020 - Regulators are highlighting the need for a comprehensive international coordination mechanism to allow the conduct of ...
Posted by Michael Wonder on 11 May 2020
Exploration of the visibility of patient input in final recommendation documentation for three health technology assessment bodies
7 May 2020 - Health technology assessment recommendations informed by patient concerns are seen to ensure democracy and legitimacy. ...
Posted by Michael Wonder on 23 Apr 2020
COVID-19: Critical Care Advisory Group
23 April 2020 - In April 2020, PHARMAC convened a group of clinical experts from across New Zealand for an ...
Posted by Michael Wonder on 23 Apr 2020
Recent PHARMAC funding decisions
22 April 2020 - You may have read about PHARMAC’S decision this week to scrap a lung cancer drug funding ...